Targeting a protein involved in bone disorders
Targeting TGFb In Osteogenesis Imperfecta
This study is looking at how a specific signaling process in the body might help improve bone strength and reduce fractures for people with Osteogenesis Imperfecta, and it aims to find new treatment options that could work better together.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10922813 on NIH RePORTER |
What this research studies
This research focuses on Osteogenesis Imperfecta (OI), a brittle bone disorder caused by genetic mutations affecting collagen production. The team is investigating the role of TGFβ signaling in bone health and how it may contribute to treatment resistance in patients. By exploring new therapeutic approaches, including the potential for combinatorial therapies, the research aims to improve bone density and reduce fracture risk in individuals with OI. The study will involve both laboratory experiments and clinical assessments to evaluate the effectiveness of these new strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Osteogenesis Imperfecta, particularly those who have not responded well to existing treatments.
Not a fit: Patients with Osteogenesis Imperfecta who are not genetically predisposed to the types of mutations being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that significantly improve bone health and quality of life for patients with Osteogenesis Imperfecta.
How similar studies have performed: Previous research has shown promise in targeting TGFβ signaling in animal models of Osteogenesis Imperfecta, indicating potential for success in human applications.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Bae, Yangjin — Baylor College of Medicine
- Study coordinator: Bae, Yangjin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.